Ascertain
1245 Broadway, 20th Floor, New York, NY, 10001, United States
Overview
Ascertain, a healthcare technology company empowering care teams with AI, helps health systems, payers, and independent provider groups streamline operations and reduce administrative burden. Customers can either deploy Ascertain Automate, an enterprise software platform that uses agentic AI to automate high-volume administrative workflows, or engage Ascertain’s tech-enabled services, outsourcing entire workflows to Ascertain’s team, which operates the software on their behalf. From prior authorization and eligibility checks to discharge planning and patient scheduling, Ascertain’s AI agents navigate complex systems, interpret unstructured data, and integrate across fragmented platforms — enabling faster throughput, lower costs, and more time for patient care.
- Total investments
- 2
- Lead investments
- 2
- Investments · 12mo
- 0
- Active investors
- 2
Sector focus
- Artificial Intelligence (AI)
- Health Care
- Medical
Investment portfolio
- Eyetelligence
Led · Equity · May 2023
Eyetelligence develops AI-enabled software and hardware that uses retinal imaging to screen for eye and systemic health conditions. Its suite of clinically validated, regulatory-approved products is already in use in Australia, New Zealand, Europe, and Japan. The company sells through partners including Bupa Optical and George & Matilda. Eyetelligence plans to rebrand and launch in the U.S. as Optain to offer non-invasive point-of-care diagnostics aimed at faster, more cost-effective disease detection. The Ascertain investment will support expansion into American markets while Eyetelligence continues to operate under its existing brand in Australia and other international markets. The company framed the move as accelerating a shift from reactive sick-care to proactive preventive care.
- Optain
Led · Seed · May 2023
Optain Health offers a portable robotic retinal camera, integrated AI workflows, and teleophthalmology to enable rapid, non‑invasive screening for eye diseases and systemic risk (oculomics). Its platform detects diabetic retinopathy, glaucoma, age‑related macular degeneration, and assesses cardiovascular risk while delivering teleophthalmology grading in the U.S. The company was co‑created in 2023 by Aegis Ventures and builds on more than a decade of Australian R&D led by Professor Mingguang He. Optain is expanding deployments into primary care, optometry, and health systems with the goal of closing care gaps and improving outcomes with minimal specialist staffing. The company uses teleophthalmology services in the U.S.; its automated disease detection software is not for sale in the U.S. Optain is scaling globally with investments in Australian R&D to support expansion outside the U.S. Optain develops AI-enabled software and hardware that noninvasively diagnose eye and systemic health conditions in real time using photos of the eye. Its portable retinal camera and accompanying AI software enable clinicians to screen for more than 140 eye and systemic conditions at early stages. The company is led by CEO Jeff Dunkel and positions the eye as a gateway to monitor whole-person health. Optain's approach is based on over a decade of research by Professor Mingguang He of the University of Melbourne and the Centre for Eye Research Australia. The company traces its roots to Australian-founded Eyetelligence (launched in 2019), whose clinically validated and regulatory-approved AI products are commercialized across Australia, New Zealand, Europe, Japan and the Middle East. Optain intends to use recent seed funding to expand operations and development efforts.